Can Chemoradiation Improve Outcomes in Pancreatic Cancer? Edited by Victoria Stern June 19, 2026 ++++

Can Chemoradiation Improve Outcomes in Pancreatic Cancer? Edited by Victoria Stern https://www.medscape.com/viewarticle/can-chemoradiation-improve-outcomes-pancreatic-cancer-2026a1000krz June 19, 2026 Adding fluoropyrimidine-sensitized radiotherapy (CXRT) to adjuvant gemcitabine chemotherapy was not associated with improved overall survival or higher rates of grade 4/5 adverse events among patients with resected pancreatic head adenocarcinoma assessed in a phase 3 trial. However, in patients with node-negative disease, adding CXRT to chemotherapy was associated with significant improvements in both overall survival and disease-free survival. Timely ‘Nudges’ Help Spur Talks on Patient Care Goals Megan Brooks https://www.medscape.com/viewarticle/timely-nudges-help-spur-talks-patient-care-goals-2026a1000krj June 19, 2026 Well-timed prompts directed at oncologists and patients with advanced cancer can encourage discussions about care goals — though they may not be enough to spur those conversations in most cases, a new clinical trial finds. Reducing Keratinocyte Carcinoma Risk Kate Johnson https://www.medscape.com/viewarticle/oral-nicotinamide-cost-effective-reducing-keratinocyte-2026a1000kpq June 19, 2026 Oral nicotinamide was cost-effective for reducing keratinocyte carcinoma (KC) risk in US veterans with a history of the disease, according to an economic analysis of Veterans Health Administration (VHA) data. New Immune Therapy Boosts Disease Control in Prostate Cancer Frederik Joelving https://www.medscape.com/viewarticle/new-immune-therapy-boosts-disease-control-prostate-cancer-2026a1000kmn June 18, 2026 Adding an experimental immunotherapy to radiation treatment may extend disease-free survival in men with localized intermediate- or high-risk prostate cancer, according to a phase 3 trial.